Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M186,358Revenue $M51,584Net Margin (%)42.7Z-Score2.5
Enterprise Value $M190,486EPS $3.2Operating Margin %30.5F-Score5
P/E(ttm))18.4Cash Flow Per Share $3.5Pre-tax Margin (%)30.5Higher ROA y-yN
Price/Book2.510-y EBITDA Growth Rate %3.1Quick Ratio2.4Cash flow > EarningsY
Price/Sales3.85-y EBITDA Growth Rate %9.0Current Ratio2.7Lower Leverage y-yN
Price/Cash Flow7.2y-y EBITDA Growth Rate %1.9ROA % (ttm)12.8Higher Current Ratio y-yY
Dividend Yield %3.5Insider Buy (3m)0ROE % (ttm)28.8Less Shares Outstanding y-yY
Payout Ratio %63.0Shares Outstanding M6,379ROI % (ttm)21.6Gross Margin Increase y-yN

Gurus Latest Trades with PFE

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PFEVanguard Health Care Fund 2014-06-30 Add0.62%$29.02 - $32.4
($30.05)
$ 29.39-2%Add 105.23%14,934,022
PFEJoel Greenblatt 2014-06-30 Add0.27%$29.02 - $32.4
($30.05)
$ 29.39-2%Add 71.59%1,741,314
PFECharles Brandes 2014-06-30 Add0.12%$29.02 - $32.4
($30.05)
$ 29.39-2%Add 5.78%6,075,460
PFERay Dalio 2014-06-30 Add0.06%$29.02 - $32.4
($30.05)
$ 29.39-2%Add 250.56%393,008
PFEMichael Price 2014-06-30 Reduce-0.97%$29.02 - $32.4
($30.05)
$ 29.39-2%Reduce -69.14%107,100
PFEDodge & Cox 2014-06-30 Reduce-0.5%$29.02 - $32.4
($30.05)
$ 29.39-2%Reduce -23.73%48,902,097
PFEJean-Marie Eveillard 2014-06-30 Reduce-0.47%$29.02 - $32.4
($30.05)
$ 29.39-2%Reduce -70.71%2,303,762
PFEJohn Hussman 2014-06-30 Sold Out -0.04%$29.02 - $32.4
($30.05)
$ 29.39-2%Sold Out0
PFEJoel Greenblatt 2014-03-31 Add0.38%$29.66 - $32.75
($31.39)
$ 29.39-6%Add 356.54%1,014,808
PFEJohn Hussman 2014-03-31 Buy 0.04%$29.66 - $32.75
($31.36)
$ 29.39-6%New holding, 17000 sh.17,000
PFEVanguard Health Care Fund 2014-03-31 Reduce-0.48%$29.66 - $32.75
($31.36)
$ 29.39-6%Reduce -40.13%7,276,622
PFEJean-Marie Eveillard 2014-03-31 Reduce-0.19%$29.66 - $32.75
($31.39)
$ 29.39-6%Reduce -22.77%7,866,473
PFEJean-Marie Eveillard 2013-12-31 Add0.16%$28.24 - $32.2
($30.7)
$ 29.39-4%Add 23.07%10,186,005
PFEJoel Greenblatt 2013-12-31 Add0.11%$28.24 - $32.2
($30.7)
$ 29.39-4%Add 241.71%222,280
PFERonald Muhlenkamp 2013-12-31 Add0.05%$28.24 - $32.2
($30.7)
$ 29.39-4%Add 29.15%45,129
PFERay Dalio 2013-12-31 Add0.01%$28.24 - $32.2
($30.7)
$ 29.39-4%Add 102.18%110,408
PFEVanguard Health Care Fund 2013-12-31 Reduce-0.91%$28.24 - $32.2
($30.7)
$ 29.39-4%Reduce -43.19%12,153,122
PFECharles Brandes 2013-12-31 Reduce-0.22%$28.24 - $32.2
($30.7)
$ 29.39-4%Reduce -9.32%5,767,402
PFEDavid Dreman 2013-12-31 Reduce-0.15%$28.24 - $32.2
($30.7)
$ 29.39-4%Reduce -85.73%10,163
PFEDonald Yacktman 2013-12-31 Sold Out -0.01%$28.24 - $32.2
($30.7)
$ 29.39-4%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PFE is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
PFE Ray Dalio 2014-06-30393,0080.010.09+250.56%
PFE Vanguard Health Care Fund 2014-06-3014,934,0220.231.2+105.23%
PFE Joel Greenblatt 2014-06-301,741,3140.030.65+71.59%
PFE David Dreman 2014-06-3013,61500.03+14.88%
PFE Charles Brandes 2014-06-306,075,4600.12.2+5.78%
PFE James Barrow 2014-06-3060,500,0580.952.4+1.01%
PFE Prem Watsa 2014-06-30235,00000.48
PFE Ruane Cunniff 2014-06-3010,98700-0.32%
PFE Ronald Muhlenkamp 2014-06-3041,01900.21-0.36%
PFE Mario Gabelli 2014-06-301,104,0700.020.17-5.28%
PFE John Keeley 2014-06-3089,83900.05-6.31%
PFE Dodge & Cox 2014-06-3048,902,0970.771.4-23.73%
PFE Michael Price 2014-06-30107,10000.39-69.14%
PFE Jean-Marie Eveillard 2014-06-302,303,7620.040.17-70.71%
PFE John Hussman 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


PFE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
OLSON LAURIE JExecutive Vice President 2014-06-12Sell36,275$29.53-0.47view
Germano Geno JGroup President 2014-06-02Sell30,000$29.68-0.98view
YOUNG JOHN DGroup President 2014-03-17Sell9,000$31.38-6.34view
PFIZER INC10% Owner 2014-03-12Buy272,727$11167.18view
CANGIALOSI LORETTA VSr. Vice President, Controller 2014-03-04Sell102,943$32.05-8.3view
Dolsten MikaelPresident R&D 2014-03-04Sell35,789$32.58-9.79view
SUSMAN SALLYExecutive Vice President 2014-03-04Sell67,585$32.59-9.82view
PFIZER INC10% Owner 2014-02-04Buy227,261$8267.38view
DAMELIO FRANK AExecutive Vice President 2014-01-13Sell131,810$30.82-4.64view
DAMELIO FRANK AExecutive Vice President 2014-01-13Sell28,190$30.86-4.76view

Press Releases about PFE :

Quarterly/Annual Reports about PFE:

    News about PFE:

    Articles On GuruFocus.com
    I Am Sure This Pharma-Company Suits Your Portfolio Aug 28 2014 
    Higher Yielding Stocks With A Cheap EV/EBITDA Ratio And Low Debt Figures Aug 28 2014 
    Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG Aug 18 2014 
    A Strong Candidate for Investor´s Portfolios Aug 12 2014 
    Legendary Investor Irving Kahn's Top Five Stocks Aug 08 2014 
    Widely Held Guru Stocks Near 52-Week Lows Aug 05 2014 
    Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, UBS Aug 04 2014 
    Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
    Is Ken Fisher a Dividend Growth Investor? Jul 27 2014 
    Diamond Hill Capital Comments on Pfizer Inc Jul 25 2014 


    More From Other Websites
    Early data suggest Sanofi, Regeneron drug may halve heart risk Aug 31 2014
    Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress:... Aug 30 2014
    Pfizer's C. Difficile Vaccine Gets Fast Track Status Aug 29 2014
    Partnering With Big Pharma, Parexel Hits Its Stride Aug 29 2014
    Protalix/Pfizer's Elelyso Approved in Pediatric Patients Aug 29 2014
    Investors Bet AstraZeneca Megamerger Could Live Again Aug 29 2014
    Dow 30 Stock Roundup: UTX Reiterates Guidance, BA Wins $8.8B Order Aug 29 2014
    InnoPharma Announces FDA Approval of Decitabine for Injection, a Generic Version of DACOGEN® Aug 29 2014
    AstraZeneca shares rise on takeover and drug hopes Aug 29 2014
    Fed Chair Yellen's assets up 8% during 2013 Aug 28 2014
    AstraZeneca Pops on Possibility of Another Pfizer Bid Aug 28 2014
    Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO™... Aug 28 2014
    [$$] Pfizer Vaccine Candidate Gets Fast Track Aug 28 2014
    Pfizer’s Investigational Vaccine Candidate for Clostridium difficile Receives U.S. Food and Drug... Aug 28 2014
    Your first trade for Thursday Aug 27 2014
    Pfizer and Merck Collaborate to Develop Lung Cancer Therapy Aug 27 2014
    [video] Fast Money Final Trade: PFE, GDX, DOW, WFT Aug 27 2014
    Stocks little moved as S&P 500 ends above 2,000 again Aug 27 2014
    [video] Options Insight: Unusual Activities on The Dow Aug 27 2014
    [video] Facebook and Movado Downgraded, Deutsche Initiates Drugmakers Aug 27 2014

    Add Notes, Comments or Ask Questions

    User Comments

    SEENSCO
    ReplySEENSCO - 2 months ago
    PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK